Podcasts about actinic keratosis

In this episode, Mike, Jess and Émélie discuss Richard Solare, a 70 year old man who presents with red patches on his face.  To claim your Mainpro+ credit for listening to this podcast, click here:  https://cfpclearn.ca/podcast/in-the-clinic-episode-18-actinic-keratosis/ 

Nascentmc.com for medical writing assistance for your company. Visit learnAMAstyle.com for free downloads on medical writing and editing Klisyri for Actinic Keratosis: The FDA has approved tirbanibulin (Klisyri) for treating actinic keratosis (AK) on larger areas of the face or scalp, up to 100 cm². Previously approved for areas up to 25 cm² in December 2020, tirbanibulin is now available in a 350 mg package size for a 5-day topical treatment. Actinic keratosis is the most common pre-cancerous dermatological condition in the US, and this approval was based on a Phase 3 clinical study showing consistent safety and effectiveness for larger treatment areas. MDMA for PTSD: An FDA advisory panel voted 10-1 against endorsing MDMA for PTSD treatment due to flawed study data, questionable research practices, and significant drug risks. The FDA will make its final decision on August 11, but the panel's negative feedback might influence a denial. This decision could impact the approval and acceptance of other psychedelics like LSD and psilocybin for medical use. Arexvy for RSV: The FDA has approved the RSV vaccine AREXVY for preventing RSV lower respiratory tract disease in adults aged 50-59 at increased risk. Initially approved in May 2023 for adults aged 60 and older, AREXVY combines a recombinant RSV glycoprotein with an adjuvant. The approval followed a Phase III trial showing the vaccine's immune response and safety in the targeted age group. Rytelo for MDS: The FDA has approved imetelstat (RYTELO) for treating low- to intermediate-1 risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. Imetelstat, a telomerase inhibitor, demonstrated significant improvements in transfusion independence and hemoglobin levels in the IMerge Phase 3 trial. The approval was granted to Geron Corporation. Firdapse for LEMS: The FDA has approved an increased dose of amifampridine (Firdapse) from 80 mg to 100 mg for treating Lambert-Eaton myasthenic syndrome (LEMS) in adults and pediatric patients over 45 kg. Initially approved in 2018 for adults, and expanded to include children as young as 6 in 2022, the increased dose approval was based on clinical trials showing significant improvements in muscle strength. The approval was granted to Catalyst Pharmaceuticals. Nascentmc.com for medical writing assistance for your company. Visit learnAMAstyle.com for free downloads on medical writing and editing

Thank you for listening to this episode of "Health and Fitness" from the Nezpod Studios! Enjoy your night or the start of your day, spiced by our top-notch health and fitness/wellness updates coined from the best sources around the globe: made only for your utmost enjoyment and enlightenment… Click on subscribe to get more spicy episodes for free! See you again soon on the next episode of Health and Fitness Updates! Learn more about your ad choices. Visit megaphone.fm/adchoices

Thank you for listening to this episode of "Health and Fitness" from the Nezpod Studios! Enjoy your night or the start of your day, spiced by our top-notch health and fitness/wellness updates coined from the best sources around the globe: made only for your utmost enjoyment and enlightenment… Click on subscribe to get more spicy episodes for free! See you again soon on the next episode of Health and Fitness Updates! Learn more about your ad choices. Visit megaphone.fm/adchoices

Thank you for listening to this episode of "Health and Fitness" from the Nezpod Studios! Enjoy your night or the start of your day, spiced by our top-notch health and fitness/wellness updates coined from the best sources around the globe: made only for your utmost enjoyment and enlightenment… Click on subscribe to get more spicy episodes for free! See you again soon on the next episode of Health and Fitness Updates! Learn more about your ad choices. Visit megaphone.fm/adchoices

00:00 Introduction00:49 Insect bite vs. food allergy rashes – Ayurvedic Treatment 08:47 Rasoushadis In Allergy14:59 Oils Used In Itching 16:55 Oils Used For Abhyanga In Sensitive skin20:36 Ayurveda Treatment Of Actinic Keratosis24:20 Ayurvedic equivalent to sunscreen 25:00 Cashew Nuts Increases Kleda in the Body?27:03 Nose Block, Mucus Inflammation, allergy 29:52 Ear Clogging, Post Sinus infection39:03 Therapies for natural facial skin care 42:20 Eat and Drink only Hungry and Thirsty 46:44 Abhyanga in Evening? 48:45 Herbal oils to improve nourishment, muscle and bone strengthSign up to Online Course on Marma Therapy https://www.easyayurveda.com/marma1/  Sign up for Easy Ayurveda weekly video classes https://www.easyayurveda.com/video-classes/ Sign up for Easy Ayurveda Diabetes Course https://www.easyayurveda.com/diabetes/   Sign up for Treatment for Cardiac disorders Course   https://www.easyayurveda.com/heart  Subscribe to free Easy Ayurveda Email newsletter https://forms.aweber.com/form/58/2129766958.htm    Contact Dr Gururaja https://www.easyayurveda.com/gururaja/   Contact Dr Raghuram https://www.easyayurveda.com/raghuram/   Buy Easy Ayurveda EBooks https://www.easyayurveda.com/my-book/   Buy Books on Ayurveda https://www.easyayurveda.com/books/    

In this episode, we review the high-yield topic of Actinic Keratosis ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Oncology section. Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets

Actinic keratosis (AK) – also commonly known as solar keratosis – is a very common dermatological presentation in primary care, affecting large numbers of older people. It has the capacity to transform into a malignant lesion if untreated. In this podcast, Dr Roger Henderson looks at who is most at risk of AK, how it should be diagnosed, what treatment options are available, and when to consider referral to secondary care.

Stephen Tyring, MD, PhD interviewed by Harrison P Nguyen, MBA, MPH

Actinic keratoses are the second most common reason patients visit the dermatologist. In the first podcast of this educational program, Dr. Deborah Sarnoff, Clinical Professor of Dermatology, NYU, and President of the Skin Cancer Foundation, discusses the clinical characteristics of AK, including symptoms, histology, and risk for SCC development.

Welcome to this recording of June 2022's NASGP monthly lunchtime webinar, where we are joined by Dr Tony Downs for a talk on the management of actinic keratosis.As well as hosting as live events, we also publish these as a YouTube video and a podcast, and include a link to the slides in each episode's show notes.Look out for your Monday morning emails from us with details about the next talk, which in July will be on bowel cancer.Thanks for listening or watching, and hope you enjoy the talk.To view slides https://www.nasgp.org.uk/wp-content/uploads/Diagnosis-and-management-of-actinic-keratosis-by-Dr-Tony-Downs.pdf

In this latest podcast, Prof David Wilkinson (Chief Medical Officer of National Skin Cancer Centres) speaks with Dr Yevgeny (Gene) Filanovsky (a Family Physician with Cutaneous Surgery and Skin Cancer Focus at Skin Care West, Canada) about his extensive experience using topical 5 fluorouracil-calcipotriol compound to treat actinic keratosis. Dr Filanovsky describes how he got started in skin cancer medicine and came to work full-time in cutaneous surgery at Skin Care West, which utilises a team-based approach combining dermatologists and family physicians. It is quite unique in Canada and is one of the largest dermatology clinics in its province. Dr Filanovsky goes on to give a very detailed explanation of his experiences with topical 5 fluorouracil-calcipotriol compound use for actinic keratosis. He has treated over 1,000 patients with this treatment. Download his handout here and his slides here.

In this episode, Prof David Wilkinson (Deputy Vice-Chancellor at Macquarie University) speaks with Dr Francis Tan – a dedicated Skin Cancer Doctor who has practised in the field since 1994 – about daylight photodynamic therapy as a front-line treatment for actinic keratosis. In the podcast, Dr Tan speaks about his own experiences as a dedicated skin cancer practitioner over the past three decades, including the reasons he embarked in the field: namely, he liked working with his hands, and the immediacy of diagnosing and curing his patients of their ailments. ----more---- The podcast further explores daylight photodynamic therapy (PDT) and its benefits for treating actinic keratoses. Daylight PDT is fast becoming the best field treatment for these types of lesions, and Dr Tan speaks about how he uses this therapy in his practice in Queensland, particularly on the face and balding scalp. Dr Tan walks through the step-by-step process of treating patients with daylight PDT. He discusses which patients are candidates for this treatment which includes men who work outdoors and patients with a lot of sun damage. ----more---- About Presenters Professor David Wilkinson is Deputy Vice-Chancellor at Macquarie University. He is a registered general practitioner and public health medicine specialist. Since 2004, Professor Wilkinson's clinical work has focused on skin cancer medicine in primary care. He has published research papers on the topic, designed and led development of the only Master of Medicine degree in skin cancer, and helped develop and present a suite of skin cancer short courses delivered by HealthCert Education. Dr Francis Tan is a Skin Cancer Doctor at Coorparoo Skin Cancer & Skin Repair Centre in Brisbane. He graduated from The University of New South Wales in 1986. He worked in a variety of general practice surgeries throughout Australia, including clinics in Sydney, Tweed Heads, the Gold Coast, Brisbane and Cairns. Dr Tan obtained a Masters of Medicine from The University of Queensland in 2014 and holds an impressive portfolio of university-certified Professional Diplomas in Skin Cancer Medicine and related fields. He is particularly interested in using dermatoscopy to detect melanoma in situ and performing skin cancer surgery to the best of his ability for the benefit of his patients.

In this episode, we review the high-yield topic of Actinic Keratosis from the Dermatology section. --- Send in a voice message: https://anchor.fm/medbulletsstep1/message

Daniel Eisen, MD, FAAD interviewed by Silvina Pugliese, MD, FAAD

How often do physicians vote in elections compared with the general population? Find out about this and more in today's PV Roundup podcast.

Photodynamic therapy (PDT) has become a preferred treatment of field cancerization. Dr. Vincent DeLeo talks to Dr. Martin Miller about results from a split-sided study evaluating the efficacy of CO2 laser ablative fractional resurfacing pretreatment followed by conventional PDT for treatment of actinic keratoses (AKs). They discuss the clinical benefits of PDT for treatment of AKs as well as future directions for this combination therapy for nonmelanoma skin cancers. *  *  * We also bring you the latest in dermatology news and research: High-fat, high-sugar diet may promote adult acne It's official: COVID-19 was bad for health care business If you reopen it, will they come? *  *  * Key takeaways from this episode: Photodynamic therapy (PDT) provides consistent predictable results and healing periods without variations in response seen with topical therapies. In a split-sided study, pretreatment with CO2 laser ablative fractional resurfacing in combination with conventional PDT showed increased efficacy of AK clearance vs. conventional PDT alone. This combination therapy showed clearance of superficial basal cell carcinoma, but nodular basal cell carcinoma and squamous cell carcinoma in situ persisted at 6 months. Side effects of treatment included hypopigmentation in face and scalp areas on the laser-treated side. Future directions for treatment may include aminolevulinic acid gel 10% with standard PDT as well as combination with a red-light source to achieve deeper penetration into the skin. Hosts: Nick Andrews, Vincent A. DeLeo, MD (Keck School of Medicine of the University of Southern California, Los Angeles) Guest: Martin B. Miller, MD (University of California, San Francisco) Disclosures: Dr. DeLeo is a consultant for Estée Lauder. Dr. Miller received grant support and study drug from DUSA Pharmaceuticals Inc. Show notes by: Alicia Sonners, Melissa Sears *  *  * You can find more of our podcasts at http://www.mdedge.com/podcasts      Email the show: podcasts@mdedge.com Interact with us on Twitter: @MDedgeDerm

Feature Interview (13:30) – Our very own Dr. Tom McGovern shares his expertise as a MOHS surgery and skin cancer specialist, covering what we need to know about risk, prevention, and treatment during Skin Cancer Awareness Month. Also in this episode: Background Info (01:00) – PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma (https://doi.org/10.1056/NEJMoa1805131) Randomized Trial of Four Treatment Approaches for Actinic Keratosis (https://doi.org/10.1056/NEJMoa1811850) Medical Trivia (Answer at 38:45) – The earliest cases of skin cancer diagnosed by a physician occurred in 1775 London by Sir Percival Pott. The anatomic location of squamous cell carcinomas in this group of men helped him discover the first environmental cause of cancer - and in this case - it was not from sunshine. What occupational group was susceptible? As a hint, we see this group in a famous 1964 movie starring Dick van Dyke and Julie Andrews. ------ www.redeemerradio.com www.cathmed.org Follow us on Facebook: @DoctorDoctorShow Submit your question(s): Text (Holy Cross College text line) - 260-436-9598 Online - www.RedeemerRadio.com/Doctor E-mail - Doctor@RedeemerRadio.com Subscribe to the Podcast: iTunes | Google Play | SoundCloud | RSS

Neal Bhatia, MD stopped by the Dermcast studios during the SDPA’s Annual Summer Dermatology Conference 2018, held in Seattle, Washington, to discuss actinic keratosis and the best modalities of treatment currently available.

Dr Kirk Barber speaks with Dr Sheetal Sapra, a dermatologist and co-founder of the Institute of Cosmetic and Laser Surgery in Oakville Ontario, about the study he co-authored examining the effectiveness, safety, and patient satisfaction of daylight-mediated methyl 5-aminolevulinate (MAL)–PDT. Dr Sapra also shares his clinical experience using this treatment and his approach to managing patient concerns and expectations.Theme music: "Start of the Day" by Lee Rosevere licensed under a Creative Commons Attribution License

Interview with Joslyn S. Kirby, MD, MS, MEd, author of Variation in the Cost of Managing Actinic Keratosis

In this lecture at the SDPA summer conference in Las Vegas, Dr. Brian Berman taught about advances in treatment of actinic keratoses.

This podcast is on Treatment and Diagnosis of Actinic Keratosis and NonwithMelanoma Skin Cancers with Linda Susan Marcus, MD and was recorded at the 2013 SDPA Fall Conference in Atlanta.

This podcast is on the Treatment of Actinic Keratosis with Jeffrey Peterson MD and was recorded at the 2013 Summer SDPA Conference in St. Louis.

Wed, 09 May 2012 14:32:40 GMT http://saveyourskin.ch/podcast/EN/3.2.1.Aktin_Keratosis.mp4 Prof. Dr. Dr. h. c. Günter Burg, MD Zürich & Prof. Dr. Walter Burgdorf, MD 2013-03-10T14:32:37Z Prof. Dr. Dr. h. c. Günter Burg, MD Zürich & Prof. Dr. Walter Burgdorf, MD no

Actinic keratosis and cutaneous squamous cell carcinoma are of increasing importance with aging and increased ultraviolet light exposure in Western societies. Efficient and well-tolerated therapy is still a matter of concern. As with tumours of other organs, new target sites and innovative drugs selectively addressing them are widely looked for. Due to the relevance for DNA synthesis and thus cell proliferation, human DNA polymerase alpha should be such a target, the more so as the three-dimensional structure of the active site has been proposed based on the application of molecular modelling methods and molecular dynamics simulations. The modelled structure of the active site was used for docking nucleotide analogues in order to design selective inhibitors. Consequently, well-fitting thymidine and guanosine analogues were synthesized and tested in vitro for their influence on normal and transformed human keratinocytes. In fact, the combination of modelling studies and in vitro tests allowed us to design antiproliferative and cytotoxic agents which are new drug candidates for the therapy of skin tumours, given the agents are no relevant substrates of nucleotide transporters (MRP-4, MRP-5) expressed by skin cancer cells. Essential kinases for nucleoside activation were detected, too, corresponding with the observed effects of nucleoside analogues. Due to the rather high molecular weight and poor solubility, however, skin penetration should be poor and thus topical therapy may require carriers to improve the uptake. This becomes feasible by lipidic and non-lipidic nanoparticles which can enhance the uptake of lipophilic agents up to 13-fold. Copyright (C) 2010 S. Karger AG, Basel